Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome have?
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome has 63 citations in the OpenAlex counts ScholarIQ stores.
When was Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome published?
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome has 2023 year in the ScholarIQ index.
What is the open-access status of Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome?
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome has gold oa status in the ScholarIQ index.
What is the DOI of Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome?
The DOI for Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome is on the source record.
What is the PMID of Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome?
The PMID for Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome is on the source record.
What is the OpenAlex record for Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome?
The OpenAlex for Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome is on the source record.